Science involves reading and writing as much as conducting experiments, says David S. Pisetsky, MD, PhD. No matter what discoveries are made in the lab, if they can’t be communicated well, how can they be used to advance the field and benefit patients? Dr. Pisetsky, the founding physician editor of The Rheumatologist, a professor of…
In this session at ACR Convergence 2023 (15W112), Ursula Fearon, PhD, Christopher Ritchlin, MD, MPH, and Jose Scher, MD, will highlight recent work that describes key processes in the pathophysiology of psoriatic arthritis, including perturbations in immune and stromal cells and the microbiome. Watch for our article for a snapshot of what these experts have…
Learn how ACR staff and volunteers support the interests of the rheumatology community in public policy efforts related to Medicare reimbursement, step therapy reform, drug pricing, supporting the medical workforce and more.
PHILADELPHIA—The fellows-in-training (FIT) programs at ACR annual meetings are highly valued educational sessions that also offer a forum for fellows to meet and connect with trainees from other programs. Fellows who were not able to meet in person during the pandemic years, particularly those who were in their second or third year of training, welcomed…
Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.
An in-person poster hall and networking lounges are among the highlights attendees can expect at ACR Convergence 2023 in San Diego, Nov. 10–15.
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.
PHILADELPHIA—Expert panelists gathered in the closing session at ACR Convergence 2022 to give their take on what they saw as some of the most notable research findings and other insights to come out of the meeting, touching on a number of topics on the leading edge of the field. COVID-19 Prophylaxis & Vaccinations Alfred Kim,…